Drug Information

Drug General Information
Drug ID
D0F2MP
Former ID
DIB019229
Drug Name
compound 13d
Drug Type
Small molecular drug
Indication Discovery agent Investigative [532338]
Structure
Download
2D MOL
Formula
C25H21N5O
InChI
InChI=1S/C25H21N5O/c1-2-4-24-22(3-1)21(9-10-26-24)23-16-28-30-17-19(15-27-25(23)30)18-5-7-20(8-6-18)29-11-13-31-14-12-29/h1-10,15-17H,11-14H2
InChIKey
SZVLDZCYMADNPG-UHFFFAOYSA-N
PubChem Compound ID
60182389
PubChem Substance ID
163720535, 174516742, 175447069, 249565800
Target and Pathway
Target(s) TGF-beta receptor type I Target Info Inhibitor [532338]
TGF-beta type II receptor Target Info Inhibitor [532338]
activin A receptor, type I Target Info Inhibitor [532338]
activin A receptor, type IB Target Info Inhibitor [532338]
Activin receptor-like kinase-1 Target Info Inhibitor [532338]
Bone morphogenetic protein receptor Target Info Inhibitor [532338]
KEGG Pathway MAPK signaling pathway
Cytokine-cytokine receptor interaction
FoxO signaling pathway
Endocytosis
TGF-beta signaling pathway
Osteoclast differentiation
Hippo signaling pathway
Adherens junction
Chagas disease (American trypanosomiasis)
Hepatitis B
HTLV-I infection
Pathways in cancer
Colorectal cancer
Pancreatic cancer
Chronic myeloid leukemiahsa04010:MAPK signaling pathway
Transcriptional misregulation in cancer
Chronic myeloid leukemiahsa04060:Cytokine-cytokine receptor interaction
Signaling pathways regulating pluripotency of stem cells
NetPath Pathway FSH Signaling Pathway
IL2 Signaling Pathway
PANTHER Pathway TGF-beta signaling pathwayP00052:TGF-beta signaling pathwayP00052:TGF-beta signaling pathway
Pathway Interaction Database Glypican 1 network
ALK1 signaling events
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
TGF-beta receptor signalingglypican_1pathway:Glypican 1 network
Beta3 integrin cell surface interactions
Integrins in angiogenesis
TGF-beta receptor signalingalk1_2pathway:ALK1 pathway
Reactome TGF-beta receptor signaling activates SMADs
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
SMAD2/3 Phosphorylation Motif Mutants in Cancer
SMAD2/3 MH2 Domain Mutants in Cancer
TGFBR2 Kinase Domain Mutants in Cancer
TGFBR1 KD Mutants in Cancer
TGFBR1 LBD Mutants in CancerR-HSA-2173789:TGF-beta receptor signaling activates SMADs
TGFBR1 LBD Mutants in Cancer
WikiPathways TGF Beta Signaling Pathway
p38 MAPK Signaling Pathway
MAPK Signaling Pathway
TGF beta Signaling Pathway
Extracellular vesicle-mediated signaling in recipient cells
Cardiac Hypertrophic Response
Signaling by TGF-beta Receptor Complex
Integrated Pancreatic Cancer Pathway
Integrated Breast Cancer PathwayWP560:TGF Beta Signaling Pathway
NRF2 pathway
Nuclear Receptors Meta-Pathway
miR-targeted genes in squamous cell - TarBase
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBase
miR-targeted genes in adipocytes - TarBase
Integrated Breast Cancer PathwayWP474:Endochondral Ossification
Ectoderm Differentiation
Mesodermal Commitment Pathway
Endoderm Differentiation
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
Hair Follicle Development: Induction (Part 1 of 3)
Signaling by BMP
Integrated Breast Cancer Pathway
Heart Development
BMP Signalling and Regulation
References
Ref 532338Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
Ref 532338Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.